Regulatory and Clinical

The clearance allows for the marketing of a new non-invasive treatment.

Company to cut emissions 44% by 2030 and end all litigation.

The article was published on November 4, 2025.

The company will present at the American Society of Hematology 67th Annual Meeting.

Rein Therapeutics received FDA clearance to resume its Phase 2 trial.

The study results were published in the peer-reviewed journal eBioMedicine.